A review : The Relationships Between Ovary Disease and Tumor Marker
DOI:
https://doi.org/10.36320/ajb/v14.i3.11458Keywords:
Ovary Disease, Tumor Marker, fallopian tube, uterus, ovaryAbstract
The ovary is an organ found in the female reproductive system that produces an ovum. When released, this travels down the fallopian tube into the uterus, where it may become fertilized by a sperm. There is an ovary found on each side of the body. The ovaries also secrete hormones that play a role in the menstrual cycle and fertility. The ovary progresses through many stages beginning in the prenatal period through menopause. It is also an endocrine gland because of the various hormones that it secrete.
The ovary starts secreting more and more hormones at puberty. The hormones trigger the development of secondary sex traits. Starting with adolescence, the ovary undergoes structural and functional changes. The ability of the ovaries to control hormones makes them crucial to fertility and conception. A number of feedback mechanisms are stimulated when egg cells, or oocytes, are expelled from the Fallopian tube, which changes the hormone levels in the body.
Ovaries release progesterone, estrogen, testosterone, and inhibin at sexual maturity. The adrenal glands and ovaries in women create 50% of the body's testosterone, which is then immediately delivered into the bloodstream. Estrogen is in charge of the maturation and maintenance of the reproductive organs in their mature functional state, as well as the appearance of secondary sex characteristics in females during puberty. The uterus and mammary glands are prepared for pregnancy and breastfeeding, respectively, by progesterone. Progesterone and estrogen work together to promote endometrial changes associated with the menstrual cycle.
Downloads
References
Colvin; Wingo, C.; Abdullatif; and Hussein. (2013-01-01). "Anatomy of female puberty: The clinical relevance of developmental changes in the reproductive system". Clinical Anatomy. 26 (1): 115–129. DOI: https://doi.org/10.1002/ca.22164
Richards, JoAnne S.; Pangas, Stephanie A. (2010-04-01). "The ovary: basic biology and clinical implications". The Journal of Clinical Investigation. 120 (4): 963–972. DOI: https://doi.org/10.1172/JCI41350
Melmed, S; Polonsky, KS; Larsen, PR; Kronenberg, HM (2011). WilliamsTextbook of Endocrinology (12th ed.). Saunders. P. 595. ISBN 978-1437703245.
Marieb and Elaine (2013). Anatomy & physiology. Benjamin-Cummings. P. 903. ISBN 9780321887603.
Daftary, Shirish; Chakravarti, Sudip (2011). Manual of Obstetrics, 3rd Edition. Elsevier. Pp. 1-16. ISBN 9788131225561.
Hoffman, Barbara L., Williams, J. Whitridge (John Whitridge), 1866-1931. (2nd ed.). Williams gynecology. New York: McGraw-Hill Medical. 2012. ISBN 9780071716727. OCLC 779244257.
Ramirez-Gonzalez, Aj.; Vaamond-Lemos, R.; Filho, CJ. and Varghese, A. March 2016. Overview of the Female Reproductive System. DOI: https://doi.org/10.1007/978-1-4939-3402-7_2
Bosetti C, Scotti L, Negri E, Talamini R, Levi F, Franceschi S et al.( 2006): Benign ovarian cysts and breast cancer risk. Int. J. Cancer, 119(7):1679-1682. DOI: https://doi.org/10.1002/ijc.22016
Knight JA, Lesosky M, Blackmore KM, Voigt LF, Holt VL, Bernstein L et al. (2008):Ovarian cysts and breast cancer: results from the Women's Contraceptive and Reproductive Experiences Study. Breast Cancer Res. Gynecol Treat. , 109(1):157-164. DOI: https://doi.org/10.1007/s10549-007-9634-4
Mandal, A and Robertson, S.(2019). What are Ovarian Cysts. Bottomley C, Bourne T(2009): Diagnosis and management of ovarian cystaccidents. Best Pract Res Clin Obstet Gynaecol. , 23(5):711-24. DOI: https://doi.org/10.1016/j.bpobgyn.2009.02.001
Stany MP, Hamilton CA(2008): Benign disorders of the ovary. Obstet Clin North Am. , 35(2):271-84. DOI: https://doi.org/10.1016/j.ogc.2008.03.004
L. Farahani and Datta. S.(2016). Benign ovarian cysts. | Volume 26, ISSUE 9, P271-275. DOI: https://doi.org/10.1016/j.ogrm.2016.06.003
Valencia Higuera.(2015). Ovarian Cysts.
Novakovic.(2017). Everything you need to know about ovarian cyst.
Umland EM, Weinstein LC, Buchanan EM. Menstruation-related disorders. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2011. P. 1393.
Lin LH, Baracat MC, Gustavo AR, et al. Androgen receptor gene polymorphism and polycystic ovary syndrome. Int J Gynaecol Obstet. 2013;120:115–118. DOI: https://doi.org/10.1016/j.ijgo.2012.08.016
Aubuchon, M and Legro, RS. Polycystic ovary syndrome: Current infertility management. Clin Obstet Gynecol. 2011;54(4):675–684. DOI: https://doi.org/10.1097/GRF.0b013e3182353c98
National Institutes of Health Department of Health and Human Services. Beyond Infertility: Polycystic Ovary Syndrome (PCOS) NIH Pub. No. 08-5863, April 2008.Available at: www.nichd.nih.gov/publications/pubs/upload/PCOS_booklet.pdf. Accessed March 27, 2013.
McFarland C. Treating polycystic ovary syndrome and infertility. MCN Am J Matern Child Nurs. 2012;37(2):116–121. DOI: https://doi.org/10.1097/NMC.0b013e31824239ce
Urbanek M. The genetics of polycystic ovary syndrome. Natl Clin PractEndocrinol Metab. 2007;3:103–111. DOI: https://doi.org/10.1038/ncpendmet0400
Marx TL, Mehta AE. Polycystic ovary syndrome: Pathogenesis and treatmentover the short and long term. Cleve Clin J Med. 2003;70(1):31–33. 36–41, 45. DOI: https://doi.org/10.3949/ccjm.70.1.31
Azziz R, Carmina E, Dewailly D, et al. Position statement: Criteria for definingpolycystic ovary syndrome as a predominantly hyper-androgenic syndrome. An Androgen Excess Society guideline. J Clin Edocrinol Metab. 2006;91:4237–4245. DOI: https://doi.org/10.1210/jc.2006-0178
Hoffman, LB.; John O. Schorge, OJ; Bradshaw,DK.; Halvorson, ML.;Joseph I. Schaffer, IJ. And. Corton, MM.(2016). Williams GYNECOLOGY. Third edition.
Shayya R, Chang RJ: Reproductive endocrinology o adolescent polycystic Ovary syndrome. BJOG 117(2):150, 2010. DOI: https://doi.org/10.1111/j.1471-0528.2009.02421.x
Dunaif A, Segal KR, Futterweit W, et al: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes.38:1165, 1989. DOI: https://doi.org/10.2337/diabetes.38.9.1165
Dunaif A, Segal KR, Shelley DR, et al: Evidence for distinctive and intrinsic Defects in insulin action in polycystic ovary syndrome. Diabetes 41:1257, 1992 DOI: https://doi.org/10.2337/diabetes.41.10.1257
Panidis D, Skiadopoulos S, Rousso D, et al: Association of acanthosis nigricans with insulin resistance in patients with polycystic ovary syndrome. Br J Dermatol 132:936, 1995. DOI: https://doi.org/10.1111/j.1365-2133.1995.tb16952.x
Cruz PD Jr, Hud JA Jr: Excess insulin binding to insulin-like growth factor Receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 98(Suppl):82S, 1992. DOI: https://doi.org/10.1111/1523-1747.ep12462293
Banaszewska B, Duleba A, Spaczynski R: Lipids in polycystic ovary syndrome: Role of hyperinsulinemia and effects of metformin. Am J Obstet Gynecol 194:1266, 2006. DOI: https://doi.org/10.1016/j.ajog.2005.11.009
Talbott E, Guzick D, Clerici A, et al: Coronary heart disease risk factors in Women with polycystic ovary syndrome. Arterioscler T romb Vasc Biol 15:821, 1995. DOI: https://doi.org/10.1161/01.ATV.15.7.821
Fogel RB, Malhotra A, Pillar G, et al: Increased prevalence of obstructive Sleep Apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 86:1175, 2001. DOI: https://doi.org/10.1210/jc.86.3.1175
Vgontzas AN, Legro RS, Bixler EO, et al: Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin Resistance. J Clin Endocrinol Metab 86:517, 2001. DOI: https://doi.org/10.1210/jc.86.2.517
Nitsche K, Ehrmann DA: Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 24(5):717, 2010. DOI: https://doi.org/10.1016/j.beem.2010.08.001
Schneider JG, Tompkins C, Blumenthal RS, et al: T e metabolic syndrome in Women. Cardiol Rev 14:286, 2006. DOI: https://doi.org/10.1097/01.crd.0000233757.15181.67
Coulam CB, Annegers JF, Kranz JS: Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 61:403, 1983.
Hull MG: Epidemiology of in fertility and polycystic ovarian disease: endocrinological and demographic studies. Gynaecol Endocrinol 1:235, 1987. DOI: https://doi.org/10.3109/09513598709023610
Homburg R, Armar NA, Eshel A, et al: Infuence of serum luteinising hormone Concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 297(6655):1024, 1998b. DOI: https://doi.org/10.1136/bmj.297.6655.1024
Sagle M, Bishop K, Ridley N, et al: Recurrent early miscarriage and polycystic Ovaries. BMJ 297:1027, 1988. 40-Boomsma CM, Eijkemans MJC, Hughes EG: A meta-analysis of pregnancy Outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12:673, 2006. DOI: https://doi.org/10.1136/bmj.297.6655.1027
Dokras A, Clifton S, Futterweit W, et al: Increased prevalence of anxiety Symptoms in women with polycystic ovary syndrome: systematic review and Metaanalysis. Fertil Steril 97(1):225, 2012 DOI: https://doi.org/10.1016/j.fertnstert.2011.10.022
Dokras A, Clifton S, Futterweit W, et al: Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review And metaanalysis. Obstet Gynecol 117(1):145, 2011 DOI: https://doi.org/10.1097/AOG.0b013e318202b0a4
Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome;towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, editors. Polycystic ovary syndrome. Vol. 1992. Boston, MA: Black-well Scientific; 1992. Pp. 377–84. Spritzer PM. Polycystic ovary syndrome. Arq Bras Endocrinol Metab. 2014;58:182–7.
Bednarska, S and Siejka, A.(2017). The pathogenesis and treatment of polycystic ovary syndrome: What’s new?. Adv Clin Exp Med.26(2):359–367 DOI: https://doi.org/10.17219/acem/59380
Wołczyński S, Zgliczyński W. Abnormalities of the menstrual cycle.In: Large Interna – Endocrinology. 2nd edition. Medical TribunePoland, Warsaw 2012, 561–567.
Badr D, Kurban M, Abbas O. Metformin in dermatology: An overview. J Eur Acad Dermatol Venereol. 2013;Nov, 27:1329–1335. Doi: 10.1111/jdv.12116. DOI: https://doi.org/10.1111/jdv.12116
Beck E, Scheen AJ. Metformin, an antidiabetic molecule with anticancer properties. Rev Med Liege. 2013;68(9):444–449.
Var T, Tonguc EA, Ugur M, Altinbas S, Tokmak A.(2012). Tumor markers panel and tumor size of ovarian dermoid tumors in reproductive age. Bratisl Lek Listy. 113 (2) 95–98. DOI: https://doi.org/10.4149/BLL_2012_022
Muto MG. Management of an adnexal mass 2016. Available from: http: //www.UpToDate.com.
Runowicz CD, Brewer M. Adnexal mass in pregnancy 2016. Available from: http://www.UpToDate.com.
Multani J, Kives S. Dermoid cysts in adolescents. Curr Opin Obstetr Gynecol.
;27(5):315–9.
Sharp HT. Evaluation andmanagementof ruptured ovarian cyst 2016. Available from: http://www.UpToDate.com.
O’Neill KE, Cooper AR. The approach to ovarian dermoids in adolescents and young women. J Pediatr Adolesc Gynecol. 2011;24(3):176–80 DOI: https://doi.org/10.1016/j.jpag.2010.11.006
Patel MD. Ultrasound differentiation of benign versus malignant adnexal masses 2016. Available from: http://www.UpToDate.com.
Gameraddin, BM.; Alshoabi, S. and Alarkani, Y.(2017). An unusual sonographic appearance of a dermoid cyst in a young patient. ISSN 1755-5191.
Călin Moş.(2009). Ovarian dermoid cysts: ultrasonographic findings.Medical Ultrasonography 2009, Vol. 11, no. 4, 61-66.
Sinha A, Ewies AA.(2016). Ovarian Mature Cystic Teratoma: Challenges of Surgical Management. Obstet Gynecol Int. 2016;2016:2390178. Doi:10.1155/2016/2390178. [PubMed: 27110246]. DOI: https://doi.org/10.1155/2016/2390178
Ramarajan, GM.; Yadav, C. and Hegde, A.(2016). CA 125 Elevation: A Descriptive Etiological Study. DOI: 10.7860/NJLM/2016/149842087.
Yilmaz MB, Nikolaou M, Cohen Solal A.Tumour biomarkers in hearfailure: is there a role for CA 125? Eur J Heart Fail. 2011;13(6):579-83. DOI: https://doi.org/10.1093/eurjhf/hfr022
Hung CL, Hung TC, Lai YH, Lu CS, Wu YJ, Yeh HI.Beyond malignancy: the role of carbohydrate antigen 125 in heart failure. Biomark Res. 2013;1(1):25. DOI: https://doi.org/10.1186/2050-7771-1-25
Choi WI, Qama D, Lee MY, Kwon KY. Pleural cancer antigen-125 levels in benign and malignant pleural effusions. Int J Tuberc Lung Dis. 2013; 17(5):693–97. DOI: https://doi.org/10.5588/ijtld.12.0635
Streppel MM,Vincent A, Mukherjee R et al. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012; 43(10): 1755–63. DOI: https://doi.org/10.1016/j.humpath.2012.01.005
Saldova R, Struwe WB, Wynne K et al. Exploring the glycosylation of serum CA 125. Int J Mol Sci 2013; 14: 15636-54. DOI: https://doi.org/10.3390/ijms140815636
Kelly PJ, Archbold P, Price JH, Cardwell C, McClugGage WG. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol 2010;63:169-73. DOI: https://doi.org/10.1136/jcp.2009.072355
Pyeon,YS.; Ki, DK.; Park, YJ. And Lee, MJ.(2015). Abnormally high level of CA-19-9 in a benign ovarian cyst. DOI: 10.5468/ogs.2015.58.6.530. DOI: https://doi.org/10.5468/ogs.2015.58.6.530
Duffy MJ, Sturgeon C, Lamerz R, et al.: Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010, 21:441-47. 10.1093/annonc/mdp332. DOI: https://doi.org/10.1093/annonc/mdp332
Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ: Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med. 2009, 47:750-54. 10.1515/cclm.2009.152. DOI: https://doi.org/10.1515/CCLM.2009.152
Sagi-Dain L, Lavie O, Auslander R, Sagi S: CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature. Int J Biol Markers. 2015, 30:e333-40. 10.5301/jbm.5000139. DOI: https://doi.org/10.5301/jbm.5000139
Al Zahidy, AZ.(2018). Causes and Management of Ovarian Cysts. The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (10), Page 1818-1822. DOI: https://doi.org/10.12816/0044759
McDonald JM, Modesitt SC.(2006): The incidental postmenopausal adnexalmass. Clin Obstet Gynecol.,49(3):506-16. DOI: https://doi.org/10.1097/00003081-200609000-00010
Lee, HK.; Song, JM.; Jung, CI.; Lee, SY. And Park, KE.(2016). Autoamputation of an ovarian mature cystic teratoma: a case report and a review of the literature. World Journal of Surgical Oncology. 14:217 DOI 10.1186/s12957-016-0981-7. DOI: https://doi.org/10.1186/s12957-016-0981-7
Saglam H, Atalay F, Avsar AF, Keskin HL. The predictive value of the preoperative diagnostic tests in mature cystic teratomas of the ovary. Clin J ObstetGynecol. 2018; 1: 073-081 https://doi.org/10.29328/journal.cjog.1001013. DOI: https://doi.org/10.29328/journal.cjog.1001013
KNUDSEN, BU.; TABOR, A.; MOSGAARD, B.; ANDERSEN, SE.; KJER, JJ.; HAHN-PEDERSEN, S.; TOFTAGER-LARSEN, S. and MOGENSEN, O.(2004). Management of ovarian cysts. Acta Obstet Gynecol Scand ; 83: 1012–1021. DOI: https://doi.org/10.1111/j.0001-6349.2004.00607.x
Parambath, AS.; Ramarajan, GM.; Yadav, C. and Hegde, A.(2016). CA 125 Elevation: A Descriptive Etiological Study. DOI: 10.7860/NJLM/2016/149842087. DOI: https://doi.org/10.7860/NJLM/2016/149842087
Mujawar, AS.; Kurude, NV.; Gaikwad,AH. And Patil. WV.(2018). Utility of Ovarian Tumour Marker Cancer Antigen-125 and Endocrine Hormonal Status in Polycystic Ovary Syndrome. DOI: 10.7860/JCDR/2018/36048.12120. DOI: https://doi.org/10.7860/JCDR/2018/36048.12120
AL-Ani, HK. And Rzaij, FZ.(2013). Evaluation of Cancer Antigens (CA125&CA15- 3) in some Iraqi women with polycystic ovarian syndrome. Iraqi J. Embryos and Infertility Researches Vol.(3) No.(6).
UYANIK, M.; SERTOGLU, D.; SERDAR, AM.; AYDIN, NF.; OZGURTAS, T. and KURT, I.(2016). Two Cases of the Same Family with the Unusual Elevation of CA19-9 Levels. Revista Científica da Ordem dos Médicos
Hasanzadeh, m.; Sara, M. and Shamila, T.(2010). Ovarian dermoid cyst. Professional Med J Sep ;17(3):512-515. DOI: https://doi.org/10.29309/TPMJ/2010.17.03.2898
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Shaymaa Galeel Shamran, Samah Amer Hammood , Shaymaa hussein jaber
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
